Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Current Pharmaceutical Design
Title:Predictors of Response to TNF Antagonists
Volume: 21 Issue: 2
Author(s): Eva Salgado, Jose Ramon Maneiro and Juan J. Gomez-Reino
Affiliation:
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Export Options
About this article
Cite this article as:
Salgado Eva, Ramon Maneiro Jose and Gomez-Reino Juan J., Predictors of Response to TNF Antagonists, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825124152
DOI https://dx.doi.org/10.2174/1381612820666140825124152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment
Current Medicinal Chemistry Arginyl Aminopeptidase-Like 1 (RNPEPL1) Is an Alternatively Processed Aminopeptidase with Specificity for Methionine, Glutamine, and Citrulline Residues
Protein & Peptide Letters The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hemolysis and Rhabdomyolysis after Marathon and Long Distance Running
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Emerging Peptide Therapeutics for Inflammatory Diseases
Current Pharmaceutical Biotechnology Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Interferon gama induced Tryptophan Degradation Neuropsychiatric and Immunological Consequences
Current Drug Metabolism Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism Metallosis After Swanson Spacer as Indication for Volar Synovectomy 12 Years After Implantation
Current Rheumatology Reviews Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
Clinical Cancer Drugs Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism